NKTR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -153.61% compared to Nektar Therapeutics's net margin of -49.65%. Nektar Therapeutics's return on equity of -154.23% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 429.66%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that Nektar Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than NovaBay Pharmaceuticals.

Nektar Therapeutics has a beta of 0.649, which suggesting that the stock is 35.14% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $24.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nektar Therapeutics's net income of -$37.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.94x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -153.61% compared to Nektar Therapeutics's net margin of --. Nektar Therapeutics's return on equity of -154.23% beat Oragenics's return on equity of --.

Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 429.66%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Nektar Therapeutics has higher upside potential than Oragenics, analysts believe Nektar Therapeutics is more attractive than Oragenics.

Nektar Therapeutics has a beta of 0.649, which suggesting that the stock is 35.14% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $24.1M, which are larger than Oragenics quarterly revenues of --. Nektar Therapeutics's net income of -$37.1M is lower than Oragenics's net income of -$2.5M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.94x versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -153.61% compared to Nektar Therapeutics's net margin of -2357.27%. Nektar Therapeutics's return on equity of -154.23% beat Palatin Technologies's return on equity of --.

Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 429.66%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than Nektar Therapeutics, analysts believe Palatin Technologies is more attractive than Nektar Therapeutics.

Nektar Therapeutics has a beta of 0.649, which suggesting that the stock is 35.14% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $24.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Nektar Therapeutics's net income of -$37.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.94x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -153.61% compared to Nektar Therapeutics's net margin of --. Nektar Therapeutics's return on equity of -154.23% beat Theriva Biologics's return on equity of --.

Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 429.66%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 419.93%. Given that Nektar Therapeutics has higher upside potential than Theriva Biologics, analysts believe Nektar Therapeutics is more attractive than Theriva Biologics.

Nektar Therapeutics has a beta of 0.649, which suggesting that the stock is 35.14% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $24.1M, which are larger than Theriva Biologics quarterly revenues of --. Nektar Therapeutics's net income of -$37.1M is lower than Theriva Biologics's net income of -$4.4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.94x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.